The Oscar Project: 'One Stop Shop for Clinical Research' on Danish Real World Data
Author(s)
Holm-Larsen T1, Jensen KF2, Knoth HS2, Fanoe A2, Mortensen TB1, Rehfeld C1
1Datafair, Copenhagen, Denmark, 2Roche Pharma, Copenhagen, Denmark
OBJECTIVES: Scandinavian registry data are world renown for their high validity and the ability to combine different types of health data with personal data on financials, education and employment. To retain the approval of Scandinavian citizens on data collection, Danish health data has been fiercely protected, leading to extensive processing times and limitation of use cases - especially in commercial drug development. The aim of OSCAR is to ease and increase the utilization of Danish Registry Data/Real World Data to support increased and improved personalised drug development, by introducing a secure and ethical IT platform. METHODS: OSCAR supports and develops two methods of combining health data. The first is via an encryption technology ‘secure multiparty computation’ which supports the combination of data without the need for data lake transferral. The second method is via a platform for individual patient consent based on GDPR guidelines. Hence, data in OSCAR primarily stems from Danish registries, but is also prospective 24/7 data collected via apps and wearables. OSCAR is based on a private-public partnership and includes two advisory boards, one board including all Danish data-owners and one board including Danish life science companies. RESULTS: The OSCAR project will support a number of different elements of the drug development process such as data-driven identification of business opportunities, data driven test of study design, data driven patient identification and selection, creation of artificial arms directly from electronic patient journals and data-driven Innovative pricing agreements. CONCLUSION: While the OSCAR project has yet to reach completion, the majority of OSCARS product offerings are available - prevalence studies can currently be developed in less than two months as opposed to the normal 9 months timeline. Certain offerings such as the enrolment of patients based on whole genome sequencing are however not ready for market until 2023.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB416
Topic
Economic Evaluation, Medical Technologies, Methodological & Statistical Research, Real World Data & Information Systems
Topic Subcategory
Artificial Intelligence, Machine Learning, Predictive Analytics, Digital Health, Health & Insurance Records Systems, Value of Information
Disease
No Specific Disease
Explore Related HEOR by Topic